Back to Search
Start Over
Vividion begins patient dosing in phase I trial of oral STAT3 inhibitor, VVD-130850 to treat advanced solid and haematologic tumours
- Source :
- PharmaBiz. February 7, 2024
- Publication Year :
- 2024
-
Abstract
- Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.781715814